Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SMP30 CRISPR/Cas9 KO Plasmid (h): sc-401934
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SMP30 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SMP30 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SMP30 Antibody (E-11): sc-390098
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SMP30 CRISPR/Cas9 KO Plasmid (h) | sc-401934 | 20 µg | $397.00 |
Overview
Human RGN encodes senescence marker protein 30 (SMP30/Regucalcin), a calcium-binding protein implicated in cellular calcium homeostasis, redox balance, and metabolic regulation. SMP30 has been linked to modulation of intracellular Ca2+-dependent signaling, mitochondrial function, and responses to oxidative stress, processes that influence cell survival and aging-associated phenotypes. Altered RGN/SMP30 expression has been reported across contexts involving hepatic metabolism, inflammatory stress, and tumor biology, making it relevant for dissecting pathways that couple calcium signaling to cellular stress adaptation. Studying RGN loss or dysregulation can inform mechanisms of senescence, detoxification capacity, and metabolic rewiring in human cell models.
SMP30 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RGN gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RGN together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RGN open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SMP30 protein expression.
This CRISPR knockout system enables efficient generation of RGN-deficient cell models for investigation of SMP30 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RGN exon(s) critical for SMP30 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RGN genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SMP30 CRISPR/Cas9 KO Plasmid (h) and SMP30 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RGN locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SMP30 HDR Plasmid (h) and SMP30 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RGN homology arms to support homology-directed repair at defined RGN target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.